VET01S
Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals

This document includes updated tables for the Clinical and Laboratory Standards Institute veterinary antimicrobial susceptibility testing standard VET01.

A CLSI supplement for global application.
Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals

Brian V. Lubbers, DVM, PhD, DACVCP  
Dubraska V. Diaz-Campos, DVM, PhD  
Stefan Schwarz, DVM  
Robert Bowden, BS  
Claire R. Burbick, DVM, PhD, DACVM  
Virginia R. Fajt, DVM, PhD, DACVCP  
Mark Fielder, PhD  
Lacie Gunnett, BS  
Nicole M. Holliday, BA  
Cecile Kerdraon, MS  
Cory Langston, DVM, PhD  
Sara D. Lawhon, DVM, PhD, DACVM  
Xian-Zhi Li, PhD  
Marilyn N. Martinez, PhD  
Ron A. Miller, MS, PhD  
Ian Morrissey, BSc, MBA, PhD, FRSM  
Mark G. Papich, DVM, MS  
Shabbir Simjee, MSc, PhD  
Virginia Sinnott-Stutzman, DVM, DACVECC  
Michael T. Sweeney, MS  
Maria M. Traczewski, BS, MT(ASCP)  
Darren Trott, PhD  
S. Steve Yan, PhD

Abstract

The data in the tables are valid only if the methodologies in CLSI document VET011 are followed. This standard contains information about disk and dilution susceptibility test procedures for aerobic and facultatively anaerobic bacteria. Clinicians need information from the microbiology laboratory for treating and/or confirming treatment decisions for their patients with bacterial infections and depend heavily on this information for treating their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to interpret results based on the most current breakpoints and interpretive categories for antimicrobial agents used in veterinary medicine.

The tables presented in VET01S represent the most current information for drug selection, interpretation, and quality control using the procedures standardized in VET01. Users should replace previously published tables with these new tables. Changes in the tables since the previous edition appear in boldface type.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:

P: +1.610.688.0100  F: +1.610.688.0700  E: customerservice@clsi.org  W: www.clsi.org
Copyright ©2020 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals. 5th ed. CLSI supplement VET01S. Clinical and Laboratory Standards Institute; 2020.

Previous Editions:
May 2004, July 2013, June 2015, June 2018

VET01-Ed5-S-Ed5
ISBN 978-1-68440-092-8 (Print)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)
Contents

Abstract .......................................................................................................................... i
Committee Membership ............................................................................................. iii
Overview of Changes ................................................................................................. viii
Summary of CLSI Processes for Establishing Breakpoints and Quality Control Ranges ........................................................................................................... xxvii
CLSI Reference Methods vs Commercial Methods and CLSI vs Regulatory Authority ........................................................................................................... xxviii
CLSI Veterinary-Specific Breakpoint Additions/Revisions Since January 2019 .......... xxix
Subcommittee on Veterinary Antimicrobial Susceptibility Testing Mission Statement and Responsibilities ................................................................. xxx
Instructions for Use of Tables .................................................................................... 31
References ................................................................................................................... 45
Table 1. Antimicrobial Agents That Could Be Considered for Routine Testing by Veterinary Microbiology Laboratories ........................................................... 46
Table 2A. Zone Diameter and MIC Breakpoints for Enterobacterales ...................... 53
Table 2B. Zone Diameter and MIC Breakpoints for Pseudomonas aeruginosa .......... 72
Table 2C-1. Zone Diameter and MIC Breakpoints for Staphylococcus spp. for β-Lactams and β-Lactam Combination Agents ...................................................... 76
Table 2C-2. Zone Diameter and MIC Breakpoints for Staphylococcus spp. for Non-β-Lactams ........................................................................................................ 89
Table 2D. Zone Diameter and MIC Breakpoints for Enterococcus spp. .................... 101
Table 2E. Zone Diameter and MIC Breakpoints for Streptococcus spp. ................. 107
Table 2F. Zone Diameter and MIC Breakpoints for Bordetella bronchiseptica ...... 124
Table 2G. Zone Diameter and MIC Breakpoints for Mannheimia haemolytica ..... 126
Table 2H. Zone Diameter and MIC Breakpoints for Pasteurella multocida .......... 129
Table 2I. Zone Diameter and MIC Breakpoints for Actinobacillus pleuropneumoniae . 134
Table 2J. Zone Diameter and MIC Breakpoints for Histophilus somni ................. 137
Table 3. QC Strain Culture Collection Numbers for Antimicrobial Susceptibility Tests ... 140
Table 4A. Disk Diffusion QC Ranges for Nonfastidious Organisms ....................... 142
Contents (Continued)

Table 4B. Disk Diffusion QC Ranges for Fastidious Organisms ........................................ 145
Table 4C. Disk Diffusion Reference Guide to QC Frequency ........................................... 147
Table 4D. Disk Diffusion Troubleshooting Guide .............................................................. 149
Table 5A. MIC QC Ranges for Nonfastidious Organisms ............................................... 153
Table 5B. MIC QC Ranges for Fastidious Organisms (Broth Dilution Methods) ............... 155
Table 5C. MIC QC Ranges for Anaerobes (Agar Dilution Method) ................................. 158
Table 5D. MIC QC Ranges for Anaerobes (Broth Microdilution Method) ....................... 159
Table 5E. MIC Reference Guide to QC Frequency ......................................................... 160
Table 5F. MIC Troubleshooting Guide ............................................................................. 162
Table 6. Solvents and Diluents for Preparing Stock Solutions of Antimicrobial Agents ... 166
Table 7A. Disk Diffusion Tests for Extended-Spectrum \( \beta \)-Lactamases in \textit{Klebsiella pneumoniae}, \textit{Klebsiella oxytoca}, \textit{Escherichia coli}, and \textit{Proteus mirabilis} .................................................. 168
Table 7B. Broth Microdilution Tests for Extended-Spectrum \( \beta \)-Lactamases in \textit{Klebsiella pneumoniae}, \textit{Klebsiella oxytoca}, \textit{Escherichia coli}, and \textit{Proteus mirabilis} .................................................. 170
Table 7C. Test for Detection of \( \beta \)-Lactamase Production in \textit{Staphylococcus} spp. .......... 172
Table 7D. Disk Diffusion Test for Prediction of \textit{meca} -Mediated Resistance in \textit{Staphylococcus} spp. .............................................................................................. 175
Table 7E. Vancomycin Agar Screen for \textit{Staphylococcus aureus} and \textit{Enterococcus} spp. ... 176
Table 7F. Test for Detection of Inducible Clindamycin Resistance in \textit{Staphylococcus} spp., \textit{Streptococcus} spp. \( \beta \)-Hemolytic Group, and \textit{Streptococcus pneumoniae} ............................................................................................ 178
Table 7G. Tests for Detection of High-Level Aminoglycoside Resistance in \textit{Enterococcus} spp. (Includes Disk Diffusion) .......................................................... 180

Appendix A. Suggestions for Confirming Resistant, Intermediate, or Nonsusceptible Antimicrobial Susceptibility Test Results and Organism Identification .......................... 183

Appendix B. Intrinsic Resistance .................................................................................... 188

Appendix C. Epidemiological Cutoff Values ................................................................... 196
Contents (Continued)

Appendix D. Dosage Regimens Used to Establish Susceptible Veterinary-Specific Breakpoints .......................................................... 198

Appendix E. QC Strains for Antimicrobial Susceptibility Tests .............................................. 208

Appendix F. CLSI Veterinary-Specific Breakpoint Additions/Revisions to VET01 Supplements Since 1999 ............................................................... 212

Glossary I. Antimicrobial Class and Subclass Designations, Antimicrobial Agents, and Antimicrobial Resistance Mechanisms .................................................. 219

Glossary II. Abbreviations Commonly Used for Antimicrobial Agents Incorporated Into Disks or Susceptibility Panels ......................................................... 222

Glossary III. List of Identical Abbreviations Used for More Than One Antimicrobial Agent in US Diagnostic Products ...................................................... 224

The Quality Management System Approach .............................................................................. 225

Related CLSI Reference Materials ........................................................................ 226
Overview of Changes

This supplement replaces the previous edition of the supplement, VET08, 4th ed., published in 2018. This list includes the major changes in this document. Other minor or editorial changes were made to the general formatting and to some of the table footnotes and comments. Changes to the tables since the previous edition appear in boldface type. The following are additions or changes unless otherwise noted as a “deletion.”

- General:
  - Changed document code from VET08 to VET01S to associate it with the methods standard, CLSI document VET011 (cross-references to VET01S in VET011 will be updated in the next edition of VET011)
  - Updated nomenclature:
    - Genera formerly included in the family Enterobacteriaceae reorganized to an order (Enterobacterales) containing seven families: Budviciaceae, Enterobacteriaceae, Erwiniaceae, Hafniaceae, Morganellaceae, Pectobacteriaceae, Yersiniaceae
    - Eggerthella lenta (formerly Eubacterium lentum)
  - Harmonized language and common information on methods and QC with CLSI documents M02, the M02 Disk Diffusion Reading Guide, M07, and M100
  - Revised Table 1, including:
    - Separating columns for dogs and cats
    - Expanding to five test/report groups (A to E) (ie, added new Group B to test/report groups, which resulted in relettering of former Groups B, C, and D to Groups C, D, and E, respectively; test/report groups in VET011 will be updated accordingly in the next edition of VET011)
    - Listing antimicrobial agents in alphabetical order within each test/report group
    - Revising footnotes
    - Cross-referencing new Appendix D
  - Revised Tables 2A through 2J:
    - Reorganized breakpoints within Tables 2A through 2J to be organized (with the exception of Table 2C-1):
      - First, by animal species (dogs, cats, horses, cattle, swine, and poultry)
      - Second, by alphabetical order of antimicrobial agent within each animal species (moved antimicrobial agent class or subclass to be a column heading rather than a row heading)
    - Added a general comment at the beginning of each table explaining the new organization, as applicable
  - Added general comment in each of Tables 2A through 2J indicating the location of dosage regimens used to establish the veterinary-specific breakpoints, listed in the new Appendix D, with the additional recommendation that laboratories share these dosage regimens with veterinarians, infectious diseases practitioners, clinical pharmacologists, and antimicrobial stewardship teams, if available
Summary of CLSI Processes for Establishing Breakpoints and Quality Control Ranges

The Clinical and Laboratory Standards Institute (CLSI) is an international, voluntary, not-for-profit, interdisciplinary, standards-developing, and educational organization accredited by the American National Standards Institute that develops and promotes the use of consensus-developed standards and guidelines within the health care community. These consensus standards and guidelines are developed in an open and consensus-seeking forum to cover critical areas of diagnostic testing and patient health care. CLSI is open to anyone or any organization that has an interest in diagnostic testing and patient care. Information about CLSI is found at www.clsi.org.

The CLSI Subcommittee on Veterinary Antimicrobial Susceptibility Testing reviews data from a variety of sources and studies (eg, in vitro, pharmacokinetics/pharmacodynamics, and clinical studies) to establish antimicrobial susceptibility test methods, breakpoints, and QC parameters. The details of the data necessary to establish breakpoints, epidemiological cutoff values, QC parameters, and how the data are presented for evaluation are described in CLSI document VET02.9

The subcommittee’s goal is to establish veterinary-specific breakpoints to decrease reliance on human breakpoints. However, human breakpoints are still listed in VET01S Table 2 series, identified with gray-shaded text, allowing comparison of veterinary-specific and human breakpoints. Human breakpoints are occasionally necessary to provide zones of inhibition for some categories and a breakpoint for laboratories to consider when there are no veterinary breakpoints available for some antimicrobial agents and organisms for all animal species.

Over time, a microorganism’s susceptibility to an antimicrobial agent may decrease, resulting in a lack of clinical efficacy and/or safety. In addition, microbiological methods and QC parameters may be refined to ensure more accurate and better performance of susceptibility test methods. Because of these types of changes, CLSI continually monitors and updates information in its documents. Although CLSI standards and guidelines are developed using the most current information available at the time, the field of science and medicine is always changing; therefore, standards and guidelines should be used in conjunction with clinical judgment, current knowledge, and clinically relevant laboratory test results to guide patient treatment.

Additional information, updates, and changes in this document are found in the meeting summary minutes of the Subcommittee on Veterinary Antimicrobial Susceptibility Testing at www.clsi.org.
Instructions for Use of Tables

These instructions apply to:

- **Table 1**: suggested groupings of antimicrobial agents that could be considered for routine testing and reporting by microbiology laboratories. Placement of antimicrobial agents in Table 1 is either based on approval by relevant regulatory organizations or on use consistent with good clinical practice.

- **Tables 2A through 2J**: tables for each organism group that contain:
  - Recommended testing conditions
  - Routine QC recommendations (also see Chapter 8 in VET011)
  - General comments for testing the organism group and specific comments for testing particular agent/organism combinations
  - Suggested agents that could be considered for routine testing and reporting by veterinary microbiology laboratories, as specified in Table 1 (test/report groups A, B, C, D, E)
  - Zone diameter and minimal inhibitory concentration (MIC) breakpoints

- **Tables 3 through 5**: tables for acceptable QC organisms, sources, and acceptable result ranges

- **Table 6**: table of solvents and diluents for preparing stock solutions of antimicrobial agents

- **Tables 7A through 7G**: tables describing tests to detect particular resistance types in specific organisms or organism groups (also see Chapter 7 in VET011)

I. Selecting Antimicrobial Agents for Testing and Reporting

A. Appropriate Agents for Routine Testing

Selecting the most appropriate antimicrobial agents to test and report is a decision best made by each laboratory in consultation with veterinarians, infectious diseases practitioners, clinical pharmacologists, and antimicrobial stewardship teams, if available. The recommendations for each organism group include antimicrobial agents that show acceptable *in vitro* test performance. Considerations in the assignment of antimicrobial agents to specific test/report groups include clinical efficacy, prevalence of resistance, minimizing emergence of resistance, cost, regulatory agency-approved clinical indications for use, and current consensus recommendations for first-choice and alternative agents. Tests of selected agents may be useful for infection control and/or monitoring purposes.

B. Equivalent Agents

Antimicrobial agents listed together in a single box are agents for which interpretive categories (susceptible, intermediate, or resistant) and clinical efficacy are similar. Within each box, an “or” between agents indicates agents for which cross-resistance...
and cross-susceptibility are nearly complete. Results from one agent connected by an “or” can be used to predict results for the other agent. For example, Enterobacterales susceptible to ampicillin can be considered susceptible to amoxicillin. The results obtained from testing ampicillin could be reported along with a comment that the isolate is also susceptible to amoxicillin. For drugs connected with an “or,” combined major and very major errors are fewer than 3%, and minor errors are fewer than 10%, based on a large population of bacteria tested (see CLSI documents VET029 and M2311 for description of error types). “Or” is also used for comparable agents when tested against organisms for which “susceptible-only” breakpoints are provided (eg, ampicillin or amoxicillin with Streptococcus canis). When no “or” connects agents within a box, testing of one agent cannot be used to predict results for another, owing either to discrepancies or insufficient data.

C. Test/Report Groups

The antimicrobial agents listed in groups A, B, C, D, and E in Table 1 include recommendations for appropriate reporting. Antimicrobial agents listed in groups A, C, and D in Table 1 are the agents that have been approved by regulatory agencies or authorities for treatment of diseases in the indicated host animal. Only group A and B designations are restated in the Table 2 series that lists the breakpoints and interpretive categories for species-specific breakpoints in each organism group. To avoid misinterpretation, routine reports to veterinarians should include antimicrobial agents appropriate for therapeutic use.

- **Group A** includes antimicrobial agents with veterinary-specific breakpoints and interpretive categories that are considered appropriate for inclusion in a routine, primary testing panel for food and companion animals, as well as for routine reporting of results for the specified organism groups. The recommended hierarchy for reporting is to first report group A agents over those using human breakpoints, because these compounds have demonstrated an acceptable level of correlation between in vitro susceptibility test results and clinical outcome.

- **Group B** includes antimicrobial agents with veterinary-specific breakpoints and interpretive categories that are considered appropriate for testing and selective reporting. Antimicrobial agents listed in Group B are considered by the Subcommittee on Veterinary Antimicrobial Susceptibility Testing to be “drugs of last resort,” eg, so as not to select for resistance in veterinary patients. Testing may be conducted routinely as part of an antimicrobial resistance surveillance program; however, reporting should be done cautiously and with guidance from an antimicrobial stewardship program12 and/or by generating an antibiogram.

- **Group C** includes antimicrobial agents that use human breakpoints and interpretive categories and are next in the hierarchy to report. These agents may perform adequately, but outcome for many veterinary applications has not been demonstrated. The veterinary laboratory may use its discretion to decide whether to selectively report the results from testing these agents.


<table>
<thead>
<tr>
<th>Test/Report Group</th>
<th>Animal Species</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Swine</td>
</tr>
<tr>
<td>Group C - Human Breakpoints</td>
<td>Amikacin</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Please note: The asterisks (*) indicate that the particular antibiotic is specific to the species listed.
<table>
<thead>
<tr>
<th>Test/Report Group</th>
<th>Body Site</th>
<th>Antimicrobial Agent</th>
<th>Antimicrobial Agent Class or Subclass</th>
<th>Organism</th>
<th>Disk Content</th>
<th>Interpretive Categories and Zone Diameter Breakpoints, nearest whole mm</th>
<th>Interpretive Categories and MIC Breakpoints, µg/mL</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>UTI</td>
<td>Amoxicillin-clavulanate 8-lactam combination agents</td>
<td>E. coli</td>
<td>20/10 µg</td>
<td>≥ 18</td>
<td>-</td>
<td>≤ 8/4</td>
<td>-</td>
</tr>
<tr>
<td>A</td>
<td>SST</td>
<td>Ampicillin Penicillinase-labile penicillins</td>
<td>E. coli</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>≤ 0.25</td>
<td>0.5</td>
</tr>
<tr>
<td>A</td>
<td>UTI</td>
<td>Ampicillin Penicillinase-labile penicillins</td>
<td>E. coli</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>≤ 8</td>
<td>-</td>
</tr>
<tr>
<td>A</td>
<td>SST</td>
<td>Cefazolin Cephalosporin I</td>
<td>E. coli</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>≤ 2</td>
<td>4</td>
</tr>
</tbody>
</table>
Related CLSI Reference Materials

**EP23™**  *Laboratory Quality Control Based on Risk Management.* 1st ed., 2011. This document provides guidance based on risk management for laboratories to develop quality control plans tailored to the particular combination of measuring system, laboratory setting, and clinical application of the test.

**M02**  *Performance Standards for Antimicrobial Disk Susceptibility Tests.* 13th ed., 2018. This standard covers the current recommended methods for disk susceptibility testing and criteria for quality control testing.

**M02QG**  *Disk Diffusion Reading Guide.* 1st ed., 2018. The Disk Diffusion Reading Guide provides photographic examples of the proper method for reading disk diffusion susceptibility testing results.


**M23**  *Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters.* 5th ed., 2018. This guideline discusses the necessary and recommended data for selecting appropriate breakpoints and quality control ranges for antimicrobial agents.

**M39**  *Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data.* 4th ed., 2014. This document describes methods for recording and analysis of antimicrobial susceptibility test data, consisting of cumulative and ongoing summaries of susceptibility patterns of clinically significant microorganisms.

**M45**  *Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria.* 3rd ed., 2016. This guideline informs clinical, public health, and research laboratories on susceptibility testing of infrequently isolated or fastidious bacteria that are not included in CLSI documents M02, M07, or M100. Antimicrobial agent selection, test interpretation, and quality control are addressed.

**M100**  *Performance Standards for Antimicrobial Susceptibility Testing.* 30th ed., 2020. This document includes updated tables for the Clinical and Laboratory Standards Institute antimicrobial susceptibility testing standards M02, M07, and M11.

**VET01**  *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals.* 5th ed., 2018. This standard covers the current recommended methods for disk diffusion susceptibility testing and the reference methods for determining minimal inhibitory concentrations of aerobic bacteria by broth macrodilution, broth microdilution, and agar dilution for veterinary use.

**VET02**  *Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters for Veterinary Antimicrobial Agents.* 3rd ed., 2008. This document addresses the required and recommended data needed for selection of appropriate interpretive standards and quality control guidance for new veterinary antimicrobial agents.

**VET03**  *Methods for Antimicrobial Broth Dilution and Disk Diffusion Susceptibility Testing of Bacteria Isolated From Aquatic Animals.* 2nd ed., 2020. This guideline provides the most up-to-date techniques for the determination of minimal inhibitory concentrations and zones of inhibition of aquatic bacteria and criteria for data interpretation and quality control testing.

---

*CLSI documents are continually reviewed and revised through the CLSI consensus process; therefore, readers should refer to the most current editions.*
Related CLSI Reference Materials (Continued)

VET04 Performance Standards for Antimicrobial Susceptibility Testing of Bacteria Isolated From Aquatic Animals. 3rd ed., 2020. This document includes updated tables for the Clinical and Laboratory Standards Institute veterinary antimicrobial susceptibility testing guideline VET03.

VET05 Generation, Presentation, and Application of Antimicrobial Susceptibility Test Data for Bacteria of Animal Origin. 1st ed., 2011. This report offers guidance on areas in which harmonization can be achieved in veterinary antimicrobial surveillance programs with the intent of facilitating comparison of data among surveillance programs.

VET06 Methods for Antimicrobial Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria Isolated From Animals. 1st ed., 2017. This document provides guidance for antimicrobial agent disk and dilution susceptibility testing, criteria for quality control testing, and breakpoints for fastidious and infrequently tested bacteria for veterinary use.

VET09 Understanding Susceptibility Test Data as a Component of Antimicrobial Stewardship in Veterinary Settings. 1st ed., 2019. This report provides veterinarians with the information needed to successfully acquire and interpret antimicrobial susceptibility test results. It promotes common understanding between the veterinarian and the veterinary microbiology laboratory by providing example culture and susceptibility reports and animal species-specific guidance on applying breakpoints to interpret susceptibility test results.
Sample